Cypherpunk Technologies Reports Second Quarter 2026 Financial Results
Cypherpunk Technologies (Nasdaq: CYPH) reported Q2 2026 results for the quarter ended June 30, 2026. It said Zcash (ZEC) treasury holdings rose to 323,394.38 ZEC, with an average purchase price of $341.83. Net income was $39.4M, or $0.18/share, vs a $16.6M net loss in Q2 2025. Leap Therapeutics said it reached FDA alignment on a registrational Phase 3 for sirexatamab in DKK1-high mCRC and initiated a strategic process for the program.
How this was made
The 30-second read
Why it matters
Near-term trading focus is likely on (1) how much of the quarter’s profitability is mark-to-market versus operating progress, and (2) whether the FDA-aligned Phase 3 plan and Fast Track status improve deal/financing odds for sirexatamab.
Market read
Q2 financials and the FDA-aligned Phase 3 framework create a catalyst mix, but the earnings narrative is dominated by ZEC mark-to-market.
What to watch
The release also discloses a strategic process for sirexatamab’s Phase 3 path, which could introduce dilution or deal uncertainty not captured by the headline financials.
Background
Cypherpunk combines a Zcash treasury strategy with a biotech subsidiary (Leap Therapeutics) advancing sirexatamab in DKK1-high metastatic colorectal cancer.
Ticker impact
Cypherpunk reported Q2 2026 results, including a $46.0M unrealized gain from marking its ZEC treasury to market and higher ZEC holdings.
Likely positive bias while ZEC remains elevated, but expect earnings quality and valuation to be viewed as mark-to-market driven.
The release quantifies both the ZEC treasury balance (323,394.38 ZEC) and the mark-to-market gain, plus states ZEC price moved from $243.35 to $400.09 during the quarter.
Market effects
Highlights how crypto treasury strategies can dominate reported earnings for crypto-adjacent public companies.
No clear regional market transmission beyond US-listed risk appetite.
FDA Type C alignment and Phase 3 planning can influence global biotech sentiment around biomarker-selected oncology trials.
Counterpoint
Because the earnings improvement is largely unrealized mark-to-market on ZEC, the stock may re-rate quickly if ZEC mean-reverts.
Key entities
- public_companyCypherpunk Technologies Inc.
Nasdaq-listed company reporting Q2 2026 results and ZEC treasury growth, plus biotech subsidiary updates.
- crypto_assetZcash (ZEC)
Cypherpunk’s treasury holdings are marked to market, driving a large unrealized gain in the quarter.
- subsidiaryLeap Therapeutics
Biotech subsidiary advancing sirexatamab; reported Phase 2 DeFianCe publication and FDA Type C alignment for Phase 3.
- drug_candidatesirexatamab (DKN-01)
Anti-DKK1 monoclonal antibody with Fast Track designation and a proposed biomarker-selected Phase 3 registrational path.
- regulatorFDA
Provided feedback supporting key Phase 3 design elements in a Type C meeting.
